Sun Pharmaceutical Industries Ltd. Aug. 31 announced that the Food and Drug Administration has approved its generic version of Eli Lilly’s Strattera (atomoxetine hydrochloride capsules).
Strattera is indicated for the management of attention deficit hyperactivity disorder in children ages six and older, teens, and adults, the Mumbai, India-based company said.
Sun Pharma said it received approval for six strengths of the drug including 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, and 100 mg. Annual U.S. sales for these strengths of branded and generic atomoxetine hydrochloride capsules is estimated at over $530 million, the company said.
The generic ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.